{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:09:21Z","timestamp":1759176561209},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s11938-006-0039-y","type":"journal-article","created":{"date-parts":[[2007,6,18]],"date-time":"2007-06-18T15:54:18Z","timestamp":1182182058000},"page":"201-210","source":"Crossref","is-referenced-by-count":4,"title":["Novel biological therapies for inflammatory bowel disease"],"prefix":"10.1007","volume":"9","author":[{"given":"Pieter C. F.","family":"Stokkers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Hommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"39_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri1132","volume":"3","author":"G Bouma","year":"2003","unstructured":"Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003, 3:521\u2013533.","journal-title":"Nat Rev Immunol"},{"key":"39_CR2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1126\/science.1106442","volume":"307","author":"TT MacDonald","year":"2005","unstructured":"MacDonald TT, Monteleone G: Immunity, inflammation, and allergy in the gut. Science 2005, 307:1920\u20131925.","journal-title":"Science"},{"key":"39_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri1747","volume":"6","author":"W Strober","year":"2006","unstructured":"Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9\u201320. This review focuses on the role of TLR and NOD proteins in the pathogenesis of disease, discussing the role of the disease-associated mutations in CARD15\/NOD2 in a functional context.","journal-title":"Nat Rev Immunol"},{"key":"39_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/gast.2002.33426","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122:1592\u20131608.","journal-title":"Gastroenterology"},{"key":"39_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cyto.2004.07.012","volume":"28","author":"PC Stokkers","year":"2004","unstructured":"Stokkers PC, Hommes DW: New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004, 28:167\u2013173.","journal-title":"Cytokine"},{"key":"39_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/gut.50.2.191","volume":"50","author":"H Tilg","year":"2002","unstructured":"Tilg H, van Montfrans C, van den Ende A, et al.: Treatment of Crohn\u2019s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002, 50:191\u2013195.","journal-title":"Gut"},{"key":"39_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1053\/gast.2000.20229","volume":"119","author":"RN Fedorak","year":"2000","unstructured":"Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473\u20131482.","journal-title":"Gastroenterology"},{"key":"39_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1053\/gast.2000.20196","volume":"119","author":"S Schreiber","year":"2000","unstructured":"Schreiber S, Fedorak RN, Nielsen OH, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease. Crohn\u2019s Disease IL-10 Cooperative Study Group. Gastroenterology 2000, 119:1461\u20131472.","journal-title":"Gastroenterology"},{"key":"39_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/gast.1997.v113.pm9247454","volume":"113","author":"SJ Van Deventer","year":"1997","unstructured":"Van Deventer SJ, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn\u2019s disease. Crohn\u2019s Disease Study Group. Gastroenterology 1997, 113:383\u2013389.","journal-title":"Gastroenterology"},{"key":"39_CR10","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","volume":"289","author":"L Steidler","year":"2000","unstructured":"Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352\u20131355.","journal-title":"Science"},{"issue":"Suppl 4","key":"39_CR11","first-page":"A27","volume":"128","author":"H Braat","year":"2005","unstructured":"Braat H, Steidler L, Neirynck S, et al.: Turbo-Probiotics as a tool for cell based (mucosal) delivery of interleukin-10 [abstract]. Gastroenterology 2005, 128(Suppl 4):A27.","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"39_CR12","first-page":"A685","volume":"128","author":"H Braat","year":"2005","unstructured":"Braat H, Rottiers P, Huyghebaert N, et al.: Interleukin-10 producing Lactococcus lactis for the treatment of Crohn\u2019s disease [abstract]. Gastroenterology 2005, 128(Suppl 4):A685.","journal-title":"Gastroenterology"},{"key":"39_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2036.2002.01179.x","volume":"16","author":"BE Sands","year":"2002","unstructured":"Sands BE, Winston BD, Salzberg B, et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn\u2019s disease. Aliment Pharmacol Ther 2002, 16:399\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"key":"39_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","volume":"3","author":"E Musch","year":"2005","unstructured":"Musch E, Andus T, Kruis W, et al.: Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005, 3:581\u2013586.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"39_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","volume":"52","author":"S Nikolaus","year":"2003","unstructured":"Nikolaus S, Rutgeerts P, Fedorak R, et al.: Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003, 52:1286\u20131290.","journal-title":"Gut"},{"key":"39_CR16","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","volume":"52","author":"H Tilg","year":"2003","unstructured":"Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728\u20131733.","journal-title":"Gut"},{"key":"39_CR17","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa041109","volume":"352","author":"JR Korzenik","year":"2005","unstructured":"Korzenik JR, Dieckgraefe BK, Valentine JF, et al.: Sargramostim for active Crohn\u2019s disease. N Engl J Med 2005, 352:2193\u20132201. This trial leaves the immune suppression paradigm for the treatment of Crohn\u2019s disease by boosting innate immunity with GM-CSF.","journal-title":"N Engl J Med"},{"key":"39_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088\u20131094.","journal-title":"Gastroenterology"},{"key":"39_CR19","first-page":"CD003574","volume":"1","author":"AK Akobeng","year":"2004","unstructured":"Akobeng AK, Zachos M: Tumor necrosis factor-alpha antibody for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2004, 1:CD003574.","journal-title":"Cochrane Database Syst Rev"},{"key":"39_CR20","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Van AG, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593\u20131610.","journal-title":"Gastroenterology"},{"key":"39_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/gut.50.2.206","volume":"50","author":"T Ten Hove","year":"2002","unstructured":"Ten Hove T, van Montfrans C, Peppelenbosch MP, Van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 2002, 50:206\u2013211.","journal-title":"Gut"},{"key":"39_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, Van Deventer SJ, et al.: A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 1997, 337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"39_CR23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541\u20131549.","journal-title":"Lancet"},{"key":"39_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999, 340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"39_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 2004, 350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"39_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.gastro.2005.05.064","volume":"129","author":"DW Hommes","year":"2005","unstructured":"Hommes DW, Baert F, Van Assche G, et al.: Therapy management of recent onset Crohn\u2019s disease: a controlled, randomized trial comparing step-up and topdown therapy [abstract]. Gastroenterology 2005, 129:371.","journal-title":"Gastroenterology"},{"key":"39_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348:601\u2013608.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"39_CR28","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","volume":"55","author":"SP Travis","year":"2006","unstructured":"Travis SP, Stange EF, Lemann M, et al.: European evidence based consensus on the diagnosis and management of Crohn\u2019s disease: current management. Gut 2006, 55(Suppl 1):i16-i35.","journal-title":"Gut"},{"key":"39_CR29","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/j.1572-0241.2001.04039.x","volume":"96","author":"WY Chey","year":"2001","unstructured":"Chey WY, Hussain A, Ryan C, et al.: Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001, 96:2373\u20132381.","journal-title":"Am J Gastroenterol"},{"key":"39_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","volume":"7","author":"BE Sands","year":"2001","unstructured":"Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83\u201388.","journal-title":"Inflamm Bowel Dis"},{"key":"39_CR31","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462\u20132476. Here, the results of the ACT 1 and 2 trials are described. These trials provide strong arguments for registration of IFX for the treatment of UC.","journal-title":"N Engl J Med"},{"key":"39_CR32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G Jarnerot","year":"2005","unstructured":"Jarnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805\u20131811.","journal-title":"Gastroenterology"},{"key":"39_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00054725-200403000-00002","volume":"10","author":"J Arts","year":"2004","unstructured":"Arts J, D\u2019Haens G, Zeegers M, et al.: Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004, 10:73\u201378.","journal-title":"Inflamm Bowel Dis"},{"key":"39_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV, Tremaine WJ, et al.: The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19\u201331.","journal-title":"Gastroenterology"},{"key":"39_CR35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001, 345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"39_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","volume":"100","author":"KA Papadakis","year":"2005","unstructured":"Papadakis KA, Shaye OA, Vasiliauskas EA, et al.: Safety and efficacy of adalimumab (D2E7) in Crohn\u2019s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75\u201379.","journal-title":"Am J Gastroenterol"},{"key":"39_CR37","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","volume":"99","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Hanauer S, Loftus EV, et al.: An openlabel study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn\u2019s disease. Am J Gastroenterol 2004, 99:1984\u20131989.","journal-title":"Am J Gastroenterol"},{"key":"39_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323\u2013333. The results of the phase III trial that paves the way for the second effective anti-TNF compound that can be used for treatment of Crohn\u2019s disease.","journal-title":"Gastroenterology"},{"key":"39_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.02791.x","volume":"23","author":"BG Feagan","year":"2006","unstructured":"Feagan BG, Sandborn WJ, Lichtenstein G, et al.: CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:617\u2013628.","journal-title":"Aliment Pharmacol Ther"},{"key":"39_CR40","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2003.035253","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn\u2019s disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485\u20131493.","journal-title":"Gut"},{"key":"39_CR41","first-page":"40","volume":"74","author":"CA Dinarello","year":"2005","unstructured":"Dinarello CA: Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005, 74:40\u201347.","journal-title":"J Rheumatol Suppl"},{"key":"39_CR42","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease. Gastroenterology 2005, 129:807\u2013818.","journal-title":"Gastroenterology"},{"key":"39_CR43","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa033402","volume":"351","author":"PJ Mannon","year":"2004","unstructured":"Mannon PJ, Fuss IJ, Mayer L, et al.: Anti-interleukin-12 antibody for active Crohn\u2019s disease. N Engl J Med 2004, 351:2069\u20132079.","journal-title":"N Engl J Med"},{"key":"39_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/gast.2001.26260","volume":"121","author":"FH Gordon","year":"2001","unstructured":"Gordon FH, Lai CW, Hamilton MI, et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease. Gastroenterology 2001, 121:268\u2013274.","journal-title":"Gastroenterology"},{"key":"39_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn\u2019s disease. N Engl J Med 2003, 348:24\u201332.","journal-title":"N Engl J Med"},{"key":"39_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","volume":"16","author":"FH Gordon","year":"2002","unstructured":"Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699\u2013705.","journal-title":"Aliment Pharmacol Ther"},{"key":"39_CR47","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:1912\u20131925.","journal-title":"N Engl J Med"},{"key":"39_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924\u2013933.","journal-title":"N Engl J Med"},{"key":"39_CR49","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.4049\/jimmunol.165.11.6205","volume":"165","author":"PA Carpenter","year":"2000","unstructured":"Carpenter PA, Pavlovic S, Tso JY, et al.: Non-Fc receptorbinding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 2000, 165:6205\u20136213.","journal-title":"J Immunol"},{"key":"39_CR50","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1182\/blood.V99.8.2712","volume":"99","author":"PA Carpenter","year":"2002","unstructured":"Carpenter PA, Appelbaum FR, Corey L, et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versushost disease. Blood 2002, 99:2712\u20132719.","journal-title":"Blood"},{"key":"39_CR51","doi-asserted-by":"publisher","first-page":"A493","DOI":"10.1053\/j.gastro.2005.03.046","volume":"128","author":"S Targan","year":"2005","unstructured":"Targan S, Salzberg B, Mayer L, et al.: A phase I-II study: Multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patinets refractory to treatment with IV steroids [abstract]. Gastroenterology 2005, 128:A493.","journal-title":"Gastroenterology"},{"key":"39_CR52","first-page":"A494","volume":"128","author":"DW Hommes","year":"2005","unstructured":"Hommes DW, Plevy SE, Salzberg B, et al.: Epstein Barr Virus (EBV) replication in severe active, steroid resistant ulcerative colitis (UC) patients treated with visilizumab, an anti-CD3 antibody [abstract]. Gastroenterology 2005, 128:A494.","journal-title":"Gastroenterology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-006-0039-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0039-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T12:29:54Z","timestamp":1652617794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-006-0039-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11938-006-0039-y","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}